ClinicalTrials.gg
RecruitingNCT06262126Updated Nov 3, 2026

Virtual Reality for Non-cardiac Chest Pain

An interventional study of Virtual Reality in Gastrointestinal Diseases and Chest Pain, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 200 studies in Gastrointestinal Diseases with a site in United States — 32 open to participants now, 42 under way, 5 of them phase 3. Gastrointestinal Diseases · United States.

Planned enrollment
126th of 141
10 · median 90
Started
2024
with 5 others
No phase
63 of 200
13 open now
Primary completion
2027-12
later than 25 of 41 live
Registered
186th of 200
by date
Lead sponsor
6 of 200
Mayo Clinic

Among the 200 studies in Gastrointestinal Diseases with a site in United States, this one is the 126th largest by planned enrollment of the 141 interventional ones that give a count, is one of 6 that started in 2024, is one of 63 with no phase, reaches primary completion later than 25 of the 41 other live ones, and was the 186th registered.

Gastrointestinal Diseases

549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.

Browse Gastrointestinal Diseases studies →

Open to participants now

32 of the 200 studies in Gastrointestinal Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Gastrointestinal Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if virtual reality (VR) will improve symptoms in non-cardiac chest pain (NCCP).

Read the detailed description

The primary aim of this study is to assess the overall feasibility of virtual reality for the treatment of noncardiac chest pain and identify problems, issues, or challenges that may impact the performance of a future clinical trial. As such, the study will focus on willingness to participate, patient adherence, patient retention, and burdensomeness of the intervention and survey instruments. As a lesser objective, we will assess the effectiveness of virtual reality in patients with noncardiac chest pain at improving pain severity, symptom hypervigilance, anxiety, quality of life, and resilience.

03

Conditions studied

  • Gastrointestinal Diseases
  • Chest Pain

Keywords

  • Virtual reality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptoms of non-cardiac chest pain (recurrent anginal-like or atypical chest pain)
  • Negative prior cardiac evaluation (at a minimum, including )
  • Prior esophagogastroduodenoscopy and/or barium esophagram to rule out severe esophagitis, stricture, or motility abnormality

Exclusion criteria

Exclusion Criteria:

  • Initiation of a proton pump inhibitor (PPI) within 8 weeks
  • Major concomitant illness
  • Current drug or alcohol use that that would interfere with adherence to study requirements
  • Symptoms of vertigo or dizziness that would limit tolerability of the VR headset
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    VR Arm

    Viritual Reality therapy arm. All patients will receive virtual reality therapy.

    Other: Virtual Reality

Interventions

  • OtherVirtual Reality

    Virtual Reality therapy

06

What researchers measure

Primary outcomes

  1. Measure changes in GERD symptoms using the GERDQ questionnare

    Gastroesophageal reflux disease (GERD) questionnaire (GerdQ) is a 6-item questionnaire (scale from 0 to 18) that measures heartburn, regurgitation, abdominal pain, nausea, sleep disorders, and the over-the-counter (OTC) drugs use. The score predicts the likelihood of GERD, with a score between 11-18 suggesting 89% or greater likelihood.

    Time frame: Week 2

  2. Measure changes in GERD quality of life using the GERD-HRQL questionnaire

    GERD-HRQL- Gastroesophageal reflux disease (GERD) - Health Related Quality of Life (HRQL) The scale has 15 items, which focus on heartburn symptoms, dysphagia, medication effects and health condition. Each item is scored from 0 to 5 (maximum score 75), with a higher score indicating a better QOL

    Time frame: Week 2

  3. Measure changes in esophageal symptom specific anxiety using the EHAS questionnaire

    The esophageal hypervigilance and anxiety scale (EHAS) The EHAS is a 15-item measure with two factors evaluating esophageal hypervigilance and symptom specific anxiety scored on a 0-4 Likert scale. Items are summed to yield a total score ranging from 0 - 60 (Greater hypervigilance/anxiety).

    Time frame: Week 2

  4. Measure changes in GI symptom severity using the PAGI-SYM questionnaire

    Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) The PAGI-SYM includes 6 subscales ranging from 0 (none) to 5 (very severe): heartburn/regurgitation, fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain.

    Time frame: Week 2

  5. Measure changes in GI related patient assessment of quality of life using PAGI-QOL

    Patient Assessment of Gastrointestinal Disorders-Quality of Life (PAGI-QOL) The PAGI-QOL Is an instrument scoring 30 factors each from 0 (none of the time) to 5 (all of the time). Symptoms are assessed over a 2 week period and include the 5 domains daily activities, clothing, diet and food habits, psychological well-being/distress, and relationships.

    Time frame: Week 2

Secondary outcomes

  1. Measure changes in anxiety and depression using the HADs scale

    The Hospital Anxiety and Depression Scale (HADs) consists of 14 items and consists of two subscales: anxiety and depression. Each item is rated on a four-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represents 'borderline' and 0-7 'normal'.

    Time frame: Week 2

  2. Measure changes in resilience using the brief resilience scale

    The brief resilience scale is a 6 question survey assessing resiliency with questions assessed by a 5 point Likert scale. 12-item short form survey (SF-12). The SF-12 is a 12 question survey assessing the impact of health on a patient's everyday life. The questions assess 8 domains including physical activities, social activities, pain, mental health, vitality, general health perceptions and limitations related to physical and emotional problems.

    Time frame: Week 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2027, 46 months after the start.

Of 127 non-industry interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 46 months is above that.

Counting every sponsor, half of 149 studies reached it within 24 months; a quarter within 10 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Jul 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 15, 2024
StartActual
Feb 14, 2024
Primary completionEst.
Dec 31, 2027was Jul 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Dec 31, 2027
Nov 3, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Jul 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06262126
Lead sponsor
Mayo Clinic
Responsible party
Andree H. Koop (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 15, 2024
Start date
Feb 14, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Andree Koop, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion